- Dividend Yield
- 3.43%
- Annual Dividend Payout
- $3.08
- Earnings Per Share
- $0.09
- Payout Ratio
- 3,422.2%
- Consensus Rating
- Moderate Buy
- Consensus Price Target
- $95.41 (5.8% Upside)
About Gilead Sciences
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.
Read More
